Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

NCT04585477 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.

NCT NCT04585477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04585477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Lead sponsor
Stanford University
Phase
Phase 2
Overall status
Suspended
Start date
April 8, 2021
Completion date
December 30, 2026
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, non-small cell lung cancer stage i, non-small cell lung cancer stage ii, non-small cell lung cancer stage iii